AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients

On Thursday, AbbVie Inc ABBV released topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (Elahere) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC).

The study met its primary endpoint with an objective response rate (ORR) of 51.9%.

In addition, the median duration of response (DOR), a key secondary endpoint, was 8.25 months.

The safety profile of mirvetuximab soravtansine was consistent with previous studies’ findings, and no new safety concerns were identified.

Full data from the PICCOLO study will be presented at a future medical meeting.

Mirvetuximab soravtansine is also being studied in PSOC in the Phase 3 GLORIOSA trial, in combination with bevacizumab versus bevacizumab alone in maintenance after second-line platinum-doublet therapy.

AbbVie added Elahere to its bag after a $10 billion acquisition of Immunogen Inc.

Global Elahere net revenues were $64 million, reflecting a partial quarter of sales.

In March, the FDA granted full approval for Eelahere for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal adult cancer patients treated with up to three prior therapies.

Data from the MIRASOL Phase 3 trial of Elahere versus the investigator’s choice show that Elahere treatment resulted in an overall survival benefit and reduced the risk of cancer progression by 35%.

Elahere represents AbbVie’s first approved solid tumor treatment following the recent acquisition of ImmunoGen.

Price Action: ABBV shares are up 1.08% at $167.24 at last check Thursday.

Photo via Shutterstock